BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
87.21 ^USD	+0.58%		+0.46%	-17.37%

Apr. 25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
Apr. 25	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

BIONTECH : UBS gives a Neutral rating

March 20, 2024 at 10:02 am EDT

In a research note, UBS analyst Eliana Merle has maintained his recommendation on the stock with a Neutral rating. The target price is still set at USD 110.

Latest news about BioNTech SE

Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	Apr. 25	MT
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
BIONTECH : Gets a Neutral rating from Deutsche Bank	Apr. 23	ZD
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Market outlook is uncertain, but optimism prevails	Apr. 15
BioNTech SE Announces Three-Year Follow-Up Data from Phase 1 Trial with the mRNA-Based Individualized Neoantigen-Specific Immunotherapy Candidate Autogene Cevumeran	Apr. 08	CI
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	Mar. 27	MT
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	Mar. 26	DJ
European Midday Briefing : Investors Hold Back Ahead of Key Inflation Print	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 26	DJ
BioNTech gets US agency notice over default on COVID vaccine royalties	Mar. 25	RE
Moderna, Inc. prepares for the post-Covid era	Mar. 25
BioNTech gets notice from US agency over default on COVID vaccine royalties	Mar. 25	RE
BioNTech gets notice from NIH on default on royalties	Mar. 25	RE
BioNTech SE Receives Notice of Default from the NIH	Mar. 25	CI
BIONTECH : Deutsche Bank remains Neutral	Mar. 22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	Mar. 21	MT
BIONTECH : A miss is a miss	Mar. 21

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

81.69 EUR

Average target price

106.6 EUR

Spread / Average Target

+30.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-17.37%	21.02B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B
LEGEND BIOTECH CORPORATION	-24.71%	8.24B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : UBS gives a Neutral rating

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs